Background-Recent studies have identified a polymorphism in the endothelin-converting enzyme (ECE)-1b promoter (Ϫ338C/A) that is strongly associated with hypertension in women. The polymorphism is located in a consensus binding sequence for the E2F family of transcription factors. E2F proteins are crucially involved in cell-cycle regulation, but their roles in cardiovascular function are poorly understood. Here, we investigated the potential role of E2F2 in blood pressure regulation. Methods and Results-Tail-cuff measurements of systolic and diastolic blood pressures were significantly higher in E2F2-null (E2F2 Ϫ/Ϫ ) mice than in their wild-type littermates, and in ex vivo ring assays, aortas from the E2F2 Ϫ/Ϫ mice exhibited significantly greater contractility in response to big endothelin-1. Big endothelin-1 is activated by ECE-1, and mRNA levels of ECE-1b, the repressive ECE-1 isoform, were significantly lower in E2F2 Ϫ/Ϫ mice than in wild-type mice. In endothelial cells, chromatin immunoprecipitation assays confirmed that E2F2 binds the ECE-1b promoter, and promoter-reporter assays indicated that E2F2 activates ECE-1b transcription. Furthermore, loss or downregulation of E2F2 led to a decline in ECE-1b levels, to higher levels of the membranous ECE-1 isoforms (ie, , and to deregulated ECE-1 activity. Finally, Sam68 coimmunoprecipitated with E2F2, occupied the ECE-1b promoter (chromatin immunoprecipitation), and repressed E2F2-mediated ECE-1b promoter activity (promoter-reporter assays). Conclusion-Our results identify a cell-cycle-independent mechanism by which E2F2 regulates endothelial function, arterial contractility, and blood pressure. 
catalyzes the rate-limiting step during biogenesis of ET-1. 2 The physiological importance of the conversion of BigET-1 to mature ET-1 is demonstrated by observations in ECE-1-, ET-1-, and ET A -knockout animals, which exhibit virtually identical cardiac and craniofacial abnormalities during embryonic development, 5, 8 and by the Ϸ140-fold greater vasoconstrictive potency of ET-1. 2 There are 4 isoforms of ECE-1: ECE-1a, -1b, -1c, and -1d, which are expressed via alternative promoters from the same gene located on human chromosome 1 (1p36) 9, 10 ( Figure IA of the online-only Data Supplement). These isoforms exist primarily as homodimers and localize to different subcellular regions because of their dissimilar N-termini; ECE-1a, -1c, and -1d are located on the plasma membrane, and ECE-1b is intracellular 9, 11, 12 ( Figure IB of the online-only Data Supplement). It has been shown that ECE-1b is located intracellularly in the late endosomes/ multivesicular bodies, 13 and its N-terminal leucine-based motifs are involved in this intracellular retention. Interaction of a plasma-membrane ECE-1 isoform with ECE-1b results in its intracellular localization and decreases its extracellular activity. 12, 14, 15 Therefore, the targeting signals specific for ECE-1b constitute a regulatory domain that modulates the localization and activity of other ECE-1 isoforms. 13 Recently, 2 independent clinical studies have revealed a polymorphism in the 5Ј-regulatory region of the ECE-1b gene (ECE1 C-338A, 338 bp upstream from the translation start site) that is strongly correlated with increases in systolic, diastolic, and mean BP levels in women. 16, 17 Moreover, the EDN1 K198N polymorphism in the coding region of the preproET-1 gene, previously known to be associated with BP in overweight people, 18 interacts with the ECE1 C-338A variant to influence BP levels. 17 Interestingly, the ECE1 C-338A polymorphism is located in a consensus site for the E2F family of transcription factors and alters its binding affinity specifically to E2F2. 17 However, it is unknown whether E2F2 plays a role in the regulation of ECE-1b gene expression and the pathogenesis of hypertension.
The E2F family of transcription factors regulate cell growth, differentiation, and survival. 19 The classically described mechanism by which E2F family members regulate transcription involves binding to DNA as heterodimers with members of the DP protein family and the recruitment of other regulatory elements. 19 Accumulating evidence indicates that the 9 known E2F proteins (E2F1 through E2F8) target both common and unique genes in the genome 20, 21 and that each E2F family member has diverse physiological functions that are specific to the tissue type and biological context. [22] [23] [24] The functional diversity of E2F members is exemplified by the strikingly different phenotypes found in the corresponding knockout animals. 22 The specific roles of E2F family members in regulating the vasculature, however, are poorly characterized.
Recently, we have shown that E2F1 is involved in the regulation of angiogenesis. Genetic deletion of E2F1 enhanced blood flow recovery after ischemic injury in mice. 24 To determine whether other E2F family members are involved in angiogenesis, we performed experiments in E2F2-null (E2F2 Ϫ/Ϫ ) mice. Angiogenesis was unchanged; however, the E2F2 Ϫ/Ϫ mice were hypertensive with altered vasomotion. Here, we provide genetic evidence that E2F2 regulates BP via specific regulation of endothelial ECE-1b expression, subcellular localization, and hence vascular reactivity. Furthermore, our studies reveal that Sam68, an RNA-binding protein and oncogene, acts as a novel transcription cofactor of E2F2 in the regulation of ECE-1b.
Methods

Mice
The heterozygote E2F2 ϩ/Ϫ mice were obtained from Dr Gustavo Leone's laboratory (Ohio State University) 25 and were bred, maintained, and operated on in the Center for Comparative Medicine of Northwestern University following protocols approved by the Institutional Animal Care and Use Committee. All animals were genotyped by polymerase chain reaction (PCR) of tail DNA. Age-and sex-matched E2F2 Ϫ/Ϫ , E2F2 ϩ/Ϫ , and their wild-type (WT) littermates were used.
BP Measurement
Arterial BP and heart rates from WT and E2F2 Ϫ/Ϫ mice were measured by the standard noninvasive tail-cuff method (CODA System, Kent Scientific, Torrington, Conn). 26 Measurements were performed during the day after 5 days of training. On each day of BP determination, 20 measurements were obtained and averaged for each mouse.
Aortic Ring Assay
The contractile properties of aortic arteries were analyzed by the ring assay 27 as described previously and as summarized in the Methods section of the online-only Data Supplement.
Measurement of ET-1 Peptides
Levels of ET-1 in mouse plasma and in cell culture medium were measured with a commercially available ELISA kit (Biomedica, Vienna, Austria) by following the manufacturer's instructions.
Tissue RNA Isolation and Real-Time Reverse-Transcription PCR
Tissue RNA was extracted and real-time PCR was performed as described previously. 24 Primer sequences are listed in Figure II of the online-only Data Supplement.
Plasmids and Small Interfering RNA
Human pECE-1b/C-alkaline phosphatase (AP) and pECE-1b/A-AP plasmids were provided by Dr Benoit Funalot (INSERM, France). 28 pRC/CMV-E2F1 and pRC/CMV-E2F2 plasmids were provided by Dr Farbio Martelli (IRCSS, Italy). Myc-Sam68 plasmid was provided by Dr Chi Wai Eric So (Institute of Cancer Research, Sutton, UK). Human and bovine E2F1 small interfering RNA (siRNA) and E2F2 siRNA were synthesized by Dharmacon, Inc (Lafayette, Colo). The mouse ECE-1b promoter-AP reporter plasmid was constructed by following standard cloning techniques (see the Methods section of the online-only Data Supplement for details).
Cell Culture, Plasmid and siRNA Transient Transfection, and Reporter Assays Human umbilical vein ECs (HUVECs) and bovine aortic ECs (BAECs) were obtained from ATCC (Manassas, Va), cultured as described, 24 and used within passage 5. For plasmid transfection of BAECs, TransFast (Promega, Madison, Wis) or Arrest-In (Open Biosystems, Huntsville, Ala) was used. For siRNA transfection of HUVECs, Arrest-In or RNAiFect (QIAGEN, Valencia, Calif) was used. Control ␤-Gal-expressing plasmid (pCMV-␤-Gal) was cotransfected to normalize for transduction efficiency. Chemiluminescent reporter gene assays for the detection of AP and ␤-Gal activities were performed as described previously. 24 
Isolation of Mouse Primary Lung ECs
Primary ECs were isolated from mouse lung tissues by following the published protocol 29 (see the Methods section of the online-only Data Supplement for details). The cells were used before passage 5, and the EC identity was confirmed before each experiment by staining with FITC-conjugated anti-CD31 antibody. 24 
Subcellular Fractionation, Western Blotting, and Coimmunoprecipitation
Plasma membrane and cytosolic proteins were fractionated by using the Pinpoint Cell Surface Protein Isolation Kit (Pierce Biotechnology Inc, Rockford, Ill) (see the Methods of the online-only Data Supplement for details) and then analyzed by Western blotting. 24 The primary antibodies used were anti-E2F2, anti-E2F1, anti-Sam68, anti-HA, anti-Tie-2, anti-actin (Santa Cruz Biotechnology, Inc, Santa Cruz, Calif), anti-human ECE-1 (R&D Systems, Minneapolis, Minn), anti-Calnexin (Stressgen, Ann Arbor, Mich), and anti-Myc (Cell Signaling Technology, Danvers, Mass). For coimmunoprecipitation, cell lysates were incubated overnight at 4°C with the appropriate antibody, then incubated with protein A/G plus agarose (Santa Cruz) for 1 hour at 4°C. After washing, the immunoprecipitates were eluted by boiling for 5 minutes, and extracts were analyzed by immunoblotting as described above. Band intensities were determined densitometrically with Image J software.
Chromatin Immunoprecipitation Assay
Chromatin immunoprecipitation (ChIP) assays were performed in HUVECs with a ChIP assay kit (Upstate, NY) (see the Methods section of the online-only Data Supplement for details). Primer sequences are listed in Figure II of the online-only Data Supplement.
Mass Spectrometry
Experiments followed a standard protein identification strategy 30 as described in the Methods section of the online-only Data Supplement.
Fluorescent Immunohistochemistry
Fluorescent immunohistochemical staining was performed by following standard techniques 31 (see the Methods section of the online-only Data Supplement for details), and the slides were examined under a confocal microscope (Zeiss LSM 510 META).
ECE-1 Enzymatic Activity in Intact Primary ECs
Conversion of the exogenous substrate BigET-1 (Alexis, Lausen, Switzerland) into mature ET-1 was determined in primary lung ECs after incubation with 10 Ϫ7 mol/L BigET-1 for 60 minutes in a 96-well plate at 37°C. The reaction was stopped by the addition of 1 mmol/L NaEDTA, and the ET-1 generated was measured in the culture medium with an ELISA kit (Biomedica, Vienna, Austria). The value obtained from the well without cells was considered the ELISA cross-reactivity for BigET-1 and subtracted from all the measurements in which BigET-1 had been added. The ET-1 level in each well was normalized to the quantity of cells as determined with a crystal violet staining method that we have described previously. 31 
Statistical Analysis
All values are expressed as meanϮSEM. Comparisons between 2 means were performed with an unpaired Student t test, whereas ANOVA with Fisher protected least significant differences and Bonferroni-Dunn posthoc analysis were used for comparisons of Ͼ2 means. Comparisons between concentration-response curves were performed with ANOVA for repeated measures. Significance was defined as PϽ0.05.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Loss of E2F2 Expression in Mice Results in Elevated BP and Exaggerated Arterial Contraction in Response to BigET-1
We measured BP in E2F2 Ϫ/Ϫ mice and their WT littermates and found that despite similar heart rates, the E2F2 Ϫ/Ϫ mice displayed significantly higher systolic and diastolic BPs ( Figure 1A ). Using ex vivo aortic ring assays, we compared the contractility of aortas isolated from E2F2 Ϫ/Ϫ mice and their WT littermates in response to BigET-1 and a variety of vasoactive substances. Contraction induced by KCl (30 mmol/L) and phenylephrine (1ϫ10 Ϫ9 to 3ϫ10 Ϫ6 mol/L) and relaxation in response to acetylcholine (1ϫ10
Ϫ6 mol/L) were similar in the 2 strains, but aortas from the E2F2 Ϫ/Ϫ mice exhibited significantly greater contractility mol/L) ( Figure 1B and 1C) . Because BigET-1 is converted to active ET-1 by ECE-1, thereby increasing vessel contractility, our observations suggest that the influence of E2F2 on contractility could be generated, at least in part, through the regulation of ECE-1 activity. If so, the elevated BP in E2F2 Ϫ/Ϫ mice may be attributable to an increase in ET-1 level and activity. Plasma ET-1 levels were significantly higher in E2F2 Ϫ/Ϫ mice than in WT mice ( Figure 1D) , and selective antagonism of the ET A receptor with BQ123 dramatically reduced BP in E2F2 Ϫ/Ϫ mice to levels that did not differ significantly from those in WT mice ( Figure III of the online-only Data Supplement). In addition, we found that E2F2 Ϫ/Ϫ mice express a higher level of ET A protein in the lung tissues ( Figure IV of the onlineonly Data Supplement). Collectively, these findings indicate that enhanced ET-1 biosynthesis and activity, resulting from increased ECE-1 activity, contribute to the BP elevations observed in E2F2 Ϫ/Ϫ mice.
E2F2 Regulates ECE-1b Transcription
Because recent clinical studies have identified a strong association between an E2F binding site polymorphism on the ECE-1b promoter (C-338A) and hypertension in women, 16, 17 our findings may be relevant to human disease. Accordingly, we evaluated whether E2F2 regulates ECE-1b mRNA expression in vivo via real-time reverse-transcription PCR analyses. In lung tissues, the levels of ECE-1b mRNA were 50% lower in E2F2 Ϫ/Ϫ mice than in their WT littermates (Figure 2A ), suggesting that endogenous E2F2 levels maintain basal ECE-1b expression in WT tissue; the levels of ECE-1a, -1c, and -1d mRNA, however, were similar between E2F2 Ϫ/Ϫ mice and WT controls ( Figure V of the online-only Data Supplement). Interestingly, ECE-1b mRNA levels were similar in the lung tissues from E2F1 Ϫ/Ϫ and WT mice (Figure VI of the online-only Data Supplement), indicating that the reduced ECE-1b expression observed in E2F2 Ϫ/Ϫ mice was an E2F2-specific effect.
To investigate whether E2F2-regulated ECE-1b mRNA expression is allele specific for the ECE-1b promoter, BAECs were cotransfected with an E2F2-expressing plasmid and a reporter plasmid that expressed AP from either the native (Ϫ338C) human ECE-1b promoter or the polymorphic (Ϫ338A) promoter associated with hypertension in women ( Figure 2B and Figure IA of the online-only Data Supple-
Figure 2. E2F2 regulates ECE-1b transcription. A, ECE-1b (left) and E2F2 (right) mRNA expression in mouse lung tissue. Real-time RT-PCR was performed with RNA freshly isolated from the lung tissues of E2F2
Ϫ/Ϫ mice, E2F2 ϩ/Ϫ mice, and their WT littermates (nϭ4). ECE-1b and E2F2 mRNA levels were normalized to GAPDH mRNA levels. B, Effect of E2F2 overexpression on human ECE-1b promoter activity. BAECs were cotransfected with plasmids expressing E2F1 (pE2F1) or E2F2 (pE2F2) and with plasmids expressing AP from either the native (Ϫ338C) ECE-1b promoter (pECE1b/C-AP) or the polymorphic (Ϫ338A) ECE-1b promoter (pECE1b/A-AP) that has been linked to hypertension in women (nϭ3). C, Effect of E2F2 knockdown on human ECE-1b promoter activity. The native or polymorphic human promoter-reporter plasmids were transfected with or without bovine E2F2 siRNA (nϭ3). D, Effect of E2F2 overexpression on mouse ECE-1b promoter activity. A mouse ECE-1 proximal promoter (1.6 kb) -AP (pMuECE1b-AP) was cotransfected with pE2F1 or pE2F2 (nϭ4). E, ChIP assay showing E2F2 occupation of the ECE-1b promoter in vivo. ChIP assays were performed in HUVECs with E2F2 antibody, E2F1 antibody, and control IgG. The promoter region for the dihydrofolate reductase gene (DHFR), which is regulated by both E2F1 and E2F2, was used as a positive control, and the 3Ј untranslated region served as a negative control. Data are meanϮSEM for A through D. AP activities were normalized to ␤-Gal activity (*PϽ0.05; **PϽ0.01). ment); cells were harvested 24 hours after transfection for AP activity assays. In the absence of E2F2 overexpression, the activity of the polymorphic promoter was significantly higher than native promoter activity ( Figure 2B ). Overexpression of E2F2 significantly increased the activity of both the polymorphic and native ECE-1b promoters, but the enhancement of native promoter activity was significantly greater (native, 28.7-fold; C-338A, 1.9-fold; Figure 2B ). These observations suggest that E2F2 activates ECE-1b expression, but this activation is impaired by the C-338A polymorphism. Results from similar experiments indicate that the human ECE-1b promoter is not regulated by E2F1 ( Figure 2B ). To determine whether endogenous E2F2 regulates ECE-1b promoter activity, we performed promoter-reporter assays in BAECs after knocking down endogenous E2F2 expression with siRNA. Both polymorphic and native ECE-1b promoter activity was significantly reduced in the presence of E2F2 siRNA, but the activity of the polymorphic promoter was reduced to a greater extent ( Figure 2C ).
To correlate our observations from experiments in E2F2
Ϫ/Ϫ mice with the results from our human ECE-1b promoterreporter assays, we investigated whether regulation of the mouse ECE-1b promoter is disrupted in E2F2 Ϫ/Ϫ mice. BAECs were cotransfected with a plasmid that expressed AP from a murine ECE-1b proximal (1.6 kb) promoter, which contains 3 putative E2F binding sites, and a plasmid expressing either E2F2 or E2F1. Overexpression of E2F2, but not E2F1, significantly upregulated murine ECE-1b promoter activity ( Figure 2D ), confirming that E2F2 regulates ECE-1b expression in both mice and humans.
To determine whether E2F2 physically interacts with the ECE-1b promoter, we performed ChIP assays with HUVECs. Antibodies to E2F2, but not E2F1, coprecipitated with the ECE-1b promoter, indicating that endogenous E2F2 occupies the ECE-1b promoter region in vivo and that ECE-1b is a direct transcriptional target of E2F2 ( Figure 2E ).
Sam68 Suppresses E2F2-Mediated ECE-1b Transcription
To identify cofactors that may interact with E2F2 and modulate ECE-1b regulation, we isolated nuclear protein extracts from cultured HUVECs, coimmunoprecipitated the extracts with the E2F2 antibody, resolved the E2F2-coprecipitated proteins on a 1-dimensional SDS-PAGE gel, and identified the proteins via mass spectrometry. One of the proteins identified was Sam68, an RNA-binding protein. 32 Both endogenous and overexpressed Sam68 protein coimmunoprecipitated with E2F2 ( Figure 3A and 3B) , confirming that Sam68 binds E2F2 in vivo and identifying Sam68 as a possible cofactor involved in E2F2 transactivity. We then performed ChIP assays and confirmed that Sam68, like E2F2, occupies the ECE-1b promoter region in vivo ( Figure 3C ).
To determine whether Sam68 modulates E2F2 transactivity at the ECE-1b promoter, we performed cotransfection experiments with plasmids expressing E2F2, Sam68, and the native human ECE-1b promoter-AP construct. Overexpression of Sam68 suppressed E2F2-induced ECE-1b promoter activity in a dose-dependent manner, as well as basal ECE-1b promoter activity ( Figure 3D ). Collectively, our data indicate that Sam68 is a cofactor that represses E2F2-mediated ECE-1b transcription.
Loss or Downregulation of E2F2 Expression Increases Levels of the Plasma Membrane ECE-1 Isoforms and Reduces Levels of the Intracellular ECE-1 Isoforms
Because E2F2 regulates ECE-1b transcription, we investigated whether ECE-1 protein levels differ in tissues harvested from E2F2
Ϫ/Ϫ mice and their WT littermates. Because the available antibodies cannot distinguish between the isoforms of ECE-1 (ie, ECE-1a, -1b, -1c, and -1d), we performed Western blotting with a polyclonal antibody that identifies a C-terminal epitope present in all 4 ECE-1 isoforms. Total ECE-1 protein levels in the lung tissues of E2F2 Ϫ/Ϫ and WT mice were similar ( Figure 4A ). We then isolated primary ECs from the lung tissues of E2F2 Ϫ/Ϫ and WT mice ( Figure VII of the online-only Data Supplement). To differentiate between the plasma membrane and intracellular ECE-1 isoforms, we labeled the surface of the lung ECs in culture with nonpermeable Sulfo-NHS-SS-Biotin and then isolated the plasma membrane and cytosolic protein compartments by fractionation. Compared with WT lung ECs, E2F2
Ϫ/Ϫ lung ECs displayed significantly less ECE-1 immunoreactivity in the cytosolic fraction (ie, ECE-1b immunoreactivity) and significantly greater ECE-1 immunoreactivity in the plasma membrane fraction (ie, ECE-1a, -1c, and -1d immunoreactivity; Figure 4 . Loss of E2F2 increases levels of the plasma membrane ECE-1 isoforms and reduces levels of the intracellular ECE-1 isoforms. A, Representative Western blotting for ECE-1 (top) and quantification of relative ECE-1 levels (bottom) in the whole-cell lysates from the lung tissues of E2F2 Ϫ/Ϫ mice and their WT littermates. The levels of ECE-1 were determined densitometrically, normalized to the levels of ␣-actin, and expressed as the fold difference from the levels measured in WT lung tissues. Control assessments evaluated ECE-1 levels in HUVECs and HeLa cell lysates, and recombinant human ECE-1 (rhECE-1) protein levels (nϭ6 per group; **PϽ0.01; NS, not significant vs WT lung tissue; N/A for normalization to ␣-actin). B, Western blotting analyses of ECE-1 protein levels at the plasma membrane and in the cytosol of the primary lung ECs isolated from E2F2 Ϫ/Ϫ and WT mice. Cells were fractionated with a Sulfo-NHS-SS-Biotin kit. The levels of ECE-1 in the membrane and cytosol were normalized to the levels of Tie-2 and calnexin, respectively, and expressed as the fold difference from the levels measured in WT ECs (nϭ5 per group; **PϽ0.01 vs WT). C, Confocal microscopy of mouse lung ECs stained with an anti-ECE-1 antibody (red) and counterstained with DAPI (blue) (original magnification ϫ400); representative results from 4 separate experiments are shown. The anti-ECE-1 antibody recognizes an epitope shared by all 4 ECE-1 isoforms (ECE-1a, -1b, -1c, -1d) . D, ET-1 levels in the culture media of WT and E2F2 Ϫ/Ϫ lung ECs after incubation with 10 Ϫ7 mol/L BigET-1 for 60 minutes (nϭ6 per group; ***PϽ0.001). The ET-1 levels were measured with ELISA and normalized to the quantity of cells. Figure 4B ). These results were confirmed via confocal microscopic analyses of cells immunofluorescently stained for ECE-1 ( Figure 4C) , and experiments in HUVECs yielded equivalent results: siRNA-mediated knockdown of E2F2 reduced cytoplasmic ECE-1 (ECE-1b) levels and increased plasma membrane ECE-1 (ECE-1a, -1c, -1d) levels ( Figure  VIII of the online-only Data Supplement). Importantly, the increase in plasma membrane ECE-1 in the E2F2 Ϫ/Ϫ lung ECs was associated with an enhanced conversion of exogenous BigET-1 into ET-1 ( Figure 4D ). These observations are consistent with a study by Muller et al, 13 who showed that ECE-1b decreases the expression and activity of ECE-1a, -1c, and -1d. Collectively, the results presented here and by Muller et al suggest that the enhanced contractility of E2F2 Ϫ/Ϫ aortic vessels in response to BigET-1 ( Figure 1B and 1C ) may evolve indirectly through the downregulation of late endosomal ECE-1b levels and a subsequent increase in ECE-1a, -1c, and -1d activity.
Discussion
Hypertension is a multifactorial disease in which genetic traits play an important role. 33, 34 Recent studies indicate that transcriptional regulators in both vascular ECs and smooth muscle cells can critically affect BP control. 27, 35 Our investigations provide the first evidence that E2F2, a classic cell-cycle regulator, influences BP. Data from our studies suggest that endogenous levels of E2F2 transcriptional activity in nonproliferating endothelium regulate vessel tone through the ECE-1/ET-1 system: E2F2 acts as a transactivator of ECE-1b transcription, and Sam68 functions as a cofactor that represses E2F2-induced ECE-1b transcription in ECs. Thus, the physiological state could regulate BP, at least in part, by balancing E2F2 and Sam68 activity to fine-tune ECE-1b expression. If so, deregulated E2F2 transcriptional activity (eg, in E2F2 Ϫ/Ϫ mice or in women carrying the C-338A ECE-1b promoter polymorphism) may contribute to the pathogenesis of hypertension.
The ECE-1/ET-1 system has been recognized to regulate BP through multiple mechanisms, including maintenance of the system vessel resistance and renal functions. 6,36 -38 Increasing evidence emphasizes aberrant vessel tone in the pathogenesis of hypertension. 39, 40 We observed a striking abnormality of vascular reactivity in E2F2 Ϫ/Ϫ mice. However, increased ECE-1/ET-1 activity has also been shown to increase oxidative stress 41 and to mediate angiotensin II-induced hypertension. 42 Importantly, the kidney has been shown to be both a source of ET-1 generation and an important target organ of this peptide, where it mediates natriuretic and diuretic effects through the ET B receptor subtype. 43, 44 Therefore, we cannot rule out a possible contribution of these factors to the hypertension phenotype of E2F2 Ϫ/Ϫ mice. The (C-338A) ECE-1b promoter polymorphism has been linked to hypertension in women but not in men. 16, 17 This gender difference may be partially due to the fact that the higher levels of estrogen in women suppress ET-1 synthesis to a greater extent, so women are more sensitive to the increase in ECE-1 activity. 45 However, this effect was not seen in a related study of human Alzheimer disease in which ECE-1 activity also plays an important role 28 (see below). In our experimental settings, the elevated BP existed in both female and male E2F2 Ϫ/Ϫ mice. Higher levels of basal promoter activity were observed for the polymorphic ECE-1b/A promoter than for the ECE-1b/C promoter, and E2F2 siRNA strongly inhibited both promoters, yielding comparable levels of residual activity. Nevertheless, the ECE-1b/A promoter was only marginally activated by E2F2 overexpression. This apparent discrepancy could evolve from intrinsic competition between E2F2 and other cofactors that bind to the ECE-1b promoter. Overexpression of 1 factor (eg, E2F2) could induce conformational changes in other cofactors, and interactions between the cofactor complex and their cognate cis elements in the ECE-1b/A and ECE-1b/C promoters could differ. However, this explanation has yet to be evaluated experimentally.
Funalot et al 28 have recently reported that the E2F2 binding site polymorphism in the ECE-1b promoter is associated with a lower risk of late-onset Alzheimer disease. Because the deposition of ␤-amyloid in the brain is a pathological hallmark of Alzheimer disease and ECE-1 activity degrades ␤-amyloid, 46 these data corroborate our findings regarding the regulation of ECE-1 activity by this E2F2 binding site in the ECE-1b promoter. In addition, E2F2 may have a role in other pathological conditions that have been linked to ECE-1 activity, including pulmonary hypertension, myocardial infarction, and renal failure. 47 Thus, the implications of our findings presented here may extend to a broad range of pathological conditions and normal developmental processes.
